Characterization of a new type HPV16 E7 variant isolated, from cervical cancer highest incidence area in HuBei province of China

Experimental Oncology

Volumn 26, Issue 1, 2004, Pages 48-54

  Li, Hui ^a   Zhao, Min ^a   Qiu, Xiaoping ^a   Ding, Xiaohua ^a   Tan, Yun ^a   Wu, Xinxing ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Cervical carcinoma; E7; HPV; Immunogenicity; Variation

Indexed keywords

HUMAN PAPILLOMAVIRUS 16 VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E7; PLASMID DNA; UNCLASSIFIED DRUG; VIRUS VACCINE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; PROTEIN ANTIBODY; PROTEIN E7; PROTEIN E7 MONOCLONAL ANTIBODY; PROTEIN HPV16 E7;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGENICITY; ARTICLE; BIOPSY TECHNIQUE; CANCER INCIDENCE; CELLULAR IMMUNITY; CHINA; CODON; COLORIMETRY; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE AMPLIFICATION; GENE ISOLATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN PAPILLOMAVIRUS 16 E7; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; UTERINE CERVIX CANCER; VIRUS ISOLATION; VIRUS TYPING; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; CALORIMETRY; CELL LINE; CLINICAL ARTICLE; GENE VECTOR; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; INOCULATION; NONSENSE MUTATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; SERUM; TUMOR BIOPSY;

ANIMALS; BASE SEQUENCE; CHINA; CODON, NONSENSE; FEMALE; GENETIC VECTORS; HUMANS; INCIDENCE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VARIATION (GENETICS);

EID: 1942473815     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV, and the International Biological Study on Cervical Cancer study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87: 796-801.
2. Zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996; 1288: 75-8.
3. Carraresi L, Tripodi SA, Mulder LCF, Bertini S, Nuti S, Schuerfeld K, Cintorino M, Bensi G, Rossini M, Mora M. Thymic hyperplasia and lung carcinomas in a line of mice transgenic for keratin 5-driven HPV E6/E7 oncogenes. Oncogene 2001; 20: 8148-53.
4. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20: 7888-98.
5. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad USA 1991; 88: 110-4.
6. Vousden K, Jat PS. Functional similarity between HPV16E7, SV40 large T and adenovirus E1a proteins. Oncogene 1989; 4: 153-8.
7. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the hpv E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domain for Rb binding and casein kinase II phosphorylation. Embo J 1990; 9: 153-60.
8. Firzlaff JM, Galloway DA, Eisenman RN, Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biologist 1989; 1: 44-53.
9. Firzlaff JM, Luscher B, Eisenman RN. Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc Natl Acad USA 1991; 88: 5187-91.
10. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
11. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988; 53: 539-47.
12. Muller M, Gausepohl H, de Martynoff G, Frank R, Brasseur R, Gissmann L. Identification of seroreactive regions of the papillomavirus type 16 proteins E4, E6, E7 and L1. J Gen Virol 1990; 71: 2709-17.
13. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified throgh in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995; 154: 5934-43.
14. Eschle D, Durst M, ter Meulen J, Luande J, Eberhardt HC, Pawlita M, Gissmann L. Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16. J Gen Virol 1992; 73: 1829-32.
15. Shirasawa SH, Tomita Y, Fuse A, Yamamoto T, Tanzawa H, Sekiya S, Takamizawa H, Simizu B. Structure and expression of an integrated human papillomavirus type 16 genome amplified in a cervical carcinoma cell line. J Gen Virol 1989; 70: 1913-9.
16. Jin D, Li M. Translation, molecular clone experimental guide. Sci Publ 1992; 24-8.
17. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. Gene inoculation generates immune response against human immunodeficiency virus type I. Proc Natl Acad Sci USA 1993; 90: 4156.
18. Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993; 4: 151-6.
19. Krchnak V, Vagner J, Suchankova A, Krcmar M, Ritterova L, Vonka V. Synthetic peptide derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J Gen Virol 1990; 71: 2719-24.
20. Chesters PM, Vousden KH, Edmonds C, McCance DJ. Analysis of human papillomavirus type 16 open reading frame E7 immortalizing function in rat embryo fiboblast cells. J Gen Virol 1990; 71: 449-53.
21. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic region. Proc Natl Acad Sci USA 1983; 80: 3812-5.
22. McIntyre MC, Frattini M, Grossman SR, Laimins L. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol 1993; 67: 3142-50.
23. Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, Garsky VM, Oliff A, Heimbrook DC. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol 1993; 13: 953-60.
24. Patrick DR, Oliff A, Heimbrook D. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J Biol Chem 1994; 269: 6842-50.
25. Wu EW, Clemens KE, Heck DV, Munger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J Virol 1993; 67: 2402-7.
26. Takami Y, Sasagawa T, Sudiro TM, Yutsudo M, Hakura A. Determination of the functional difference between human papillomavirus type 6 and 16 E7 protein by their 30 N-terminal amino acid residues. Virology 1992; 186: 489-95.
27. Edmonds C, Vousden KH. A point mutational analysis of human papillomavirus type 16E7 protein. J Virol 1989; 63: 2650-6.
28. Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 1992; 66: 1329-35.
29. Phelps WC, Mnger K, Yee CL, Barnes JA, Howley PM. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 1991; 65: 6922-30.
30. Storey A, Almond N, Osborn K, Crawford L. Mutation of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J Gen Virol 1990; 71: 965-70.
31. Watanabe DE, Kanda T, Sato H, Furuno A, Yoshiike K. Mutation analysis of human papillomavirns type 16 E7 function. J Virol 1990; 64: 207-14.
32. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905-10.
33. Stoppler MC, Ching K, Stoppler H, Clancy K, Schlegel R, Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 1996; 70: 6987-93.
34. Song S, Pitot HC, Lambert PF. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 1999; 73: 5887-93.
35. Hu LN, Xu B, Qi H-B, Ren H, Gu ML. Structure and variation of E6 and E7 genes of human papillomavirus type 16 from 1 case of cervical carcinoma in Chongqing. Acta Acad Med Militaris Tertiae 2002; 24: 106-8.
36. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9.
37. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-binding peptides. J Immunol 1995; 154: 5934-43.
38. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego J, Bianchi A, Saiag P, Levy JP, Guillet JG, Choppin J. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 1318 and determination of the HLA-B18-specific binding motif. Eur J Immunol 2000; 30: 2281-9.
39. Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 2000; 7: 1859-66.
40. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001; 167: 6471-9.
41. Chiriva-Internati M, Liu Y, Salati E, Zhou W, Wang Z, Grizzi F, Roman JJ, Lim SH, Hermonat PL. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol 2002; 32: 30-8.
42. Ho L, Chan SY, Chow V, Chong T, Tay SK, Villa LL, Bernard HU. Sequence variants of human papillornavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J Clin Microbiol 1991; 29: 1765-72.
43. Chan SY, Ho L, Ong CK, Chow V, Drescher B, Durst M, ter Meulen J, Villa L, Luande J, Mgaya HN. Molecular variantsof human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind. J Virol 1992; 66: 2057-66.
44. Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster W, Mavromara-Nazos P. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric virus spread and the movement of ancient human populations. J Virol 1993; 67: 6413-23.
45. Qiu X, Zhao M, Tan Y, Liu L, Li H, Dai T, Wu X. The synchronous detection of HPV, H-ras and p53 in cervical carcinoma tissues and distribution of HPV infection between the high incidence area and the common area. Exp Oncol 2002; 24: 194-7.